Paddock Laboratories, LLC. a pharmaceutical company, engages in the manufacture, distribution, and marketing of bioequivalent generic pharmaceuticals. The company also provides contract manufacturing services for over the counter and prescription pharmaceutical products in various dosage forms, such as compounding, ophthalmic/OTICS, topical, indictable, liquids/solids, orals, semi-solids, powders, tablets, capsules, enemas, and suppositories. In addition, it offers primary and secondary packaging services and controlled substances, as well as various support services. The company markets its products through distribution partners to retail pharmacies, as well as to institutional customers in...
3940 Quebec Avenue North
Minneapolis, MN 55427
Founded in 1977
Horizon Pharma plc Enters Settlement and License Agreement with Perrigo Company plc and Paddock Laboratories, LLC
May 8 15
Horizon Pharma plc announced that its affiliates have entered into a settlement and license agreement with Perrigo Company plc and its subsidiary Paddock Laboratories, LLC, collectively (Perrigo), to resolve pending patent litigation involving PENNSAID(r) (diclofenac sodium topical solution) 2% w/w (PENNSAID(r) 2%). Under the settlement and license agreement, Horizon has granted Perrigo the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the United States under Perrigo's Abbreviated New Drug Application (ANDA), beginning January 10, 2029 or earlier under certain circumstances. The agreement includes a stipulation by the parties requesting dismissal without prejudice of the lawsuits filed by Horizon in the U.S. District Court for the District of New Jersey and the U.S. District Court for the District of Delaware relating to the ANDA filed by Perrigo with the U.S. Food and Drug Administration for a generic version of PENNSAID 2%. Details of the settlement are confidential and the agreement is subject to submission to the Federal Trade Commission and the U.S. Department of Justice.